The aristolochic acid (AA) nephropathy model serves as a representative model for the progression from AKI to CKD, and targeting the NF-κB/miR-382/PTEN/AKT axis can significantly ameliorate AA-induced tubulointerstitial fibrosis (Figure 2) (95). Here, PTEN is linked to chronic kidney disease.